Apligraf®, an FDA-approved, bioengineered living-cell therapy from Organogenesis Inc., has become the first wound-healing therapy to demonstrate a significant change in the genomic profile of a treated non-healing wound, according to new research published in the January 4, 2016 isssue of Science Translational Medicine. The analysis from a multidisciplinary research team at the University of Miami, titled "A Bioengineered Living Cell Construct Activates an Acute Wound Healing Response In Venous Leg Ulcers," provides new insight on what happens to a wound's genomic profile when Apligraf is applied to a chronic venous leg ulcer (VLU), when compared to standard care with compression therapy alone. The analysis found that the application of Apligraf in conjunction with compression therapy altered specific molecular and cellular responses in the wound environment, converting the chronic wound profile to resemble an acute, healing wound profile. "This is the first time this type of detailed gene expression analysis has been conducted to evaluate the response to a wound-healing modality," said Marjana Tomic-Canic, Ph.D., Director of the Wound Healing and Regenerative Medicine Research Program at the University of Miami. "Our findings show that Apligraf can shift the gene expression profile of a chronic, non-healing ulcer to resemble a profile similar to that of an acute, healing wound. This is important as we now can use this as a guiding tool to understand healing of a chronic wound and mechanisms by which therapies can work." The research consisted of a prospective, randomized, controlled clinical trial that analyzed VLUs with less than 40 percent area reduction after four weeks of treatment with standard care with compression therapy.
Login Or Register To Read Full Story